| In millions, except per share items | Jan-31-23 | Jan-31-22 | Jan-31-21 | Jan-31-20 | Jan-31-19 | Jan-31-18 | Jan-31-17 |
| | S-1/A | S-1/A | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| 4P Therapeutics | 294.1 | 242.5 | | | | | |
| Pocono Pharmaceuticals | 1,785.6 | 1,179.6 | | | | | |
| Total revenues | 2.1 | 1.4 | 0.9 | 0.4 | 0.2 | 0.0 | 0.0 |
| Revenue growth [+] | 46.2% | 50.7% | 154.6% | 51.1% | | | |
| 4P Therapeutics | 21.3% | | | | | | |
| Pocono Pharmaceuticals | 51.4% | | | | | | |
| Foreign | | | 366.8% | | | | |
| Cost of goods sold | 3.5 | 2.4 | 0.6 | 0.5 | 0.3 | 0.0 | 0.0 |
| Gross profit | -1.4 | -1.0 | 0.4 | -0.2 | 0.0 | 0.0 | 0.0 |
| Gross margin | -67.1% | -70.7% | 38.3% | -48.1% | -17.5% | | |
| Selling, general and administrative [+] | 4.5 | 4.6 | 3.0 | 1.8 | 3.3 | 0.2 | 0.2 |
| Sales and marketing | 3.9 | 4.0 | | | | | |
| General and administrative | 0.6 | 0.6 | | | | | |
| Other selling, general and administrative | 3.9 | 4.0 | | | | | |
| Research and development | 1.0 | 0.4 | | | | | |
| Other operating expenses | -2.7 | -2.1 | | | | -2.7 | |
| EBITDA [+] | -3.8 | -3.6 | -2.4 | -1.9 | -3.3 | | |
| EBITDA growth | 5.4% | 48.7% | 28.4% | -42.4% | -231.8% | -1752.8% | |
| EBITDA margin | -183.6% | -254.6% | -258.1% | -511.9% | -1343.0% | | |
| Depreciation | 0.2 | 0.2 | 0.2 | 0.1 | 0.0 | | |
| EBITA | -4.0 | -3.8 | -2.6 | -2.0 | -3.3 | 2.5 | -0.2 |
| EBITA margin | -192.4% | -267.2% | -275.1% | -531.4% | -1358.1% | | |
| Amortization of intangibles | 0.1 | 0.1 | | | | | |
| EBIT [+] | -4.1 | -3.9 | -2.6 | -2.0 | -3.3 | 2.5 | -0.2 |
| EBIT growth | 5.5% | 51.4% | 31.8% | -40.9% | -233.2% | -1752.8% | |
| EBIT margin | -199.5% | -276.3% | -275.1% | -531.4% | -1358.1% | | |
| Non-recurring items [+] | 0.3 | 2.2 | | | | 2.5 | |
| Asset impairment | 0.3 | 2.2 | | | | 2.5 | |
| Interest expense | 0.0 | 0.1 | 0.3 | 0.1 | | | |
| Interest expense | 0.0 | 0.1 | 0.3 | 0.1 | | | |
| Other income (expense), net [+] | | 0.1 | -0.1 | -0.7 | | -2.7 | |
| Gain (loss) on debt retirement | | 0.1 | 0.0 | | | | |
| Gain (loss) on derivative instruments | | -0.2 | 0.0 | 0.1 | | | |
| Other non-ooperating expenses | | | | -0.8 | | | |
| Other | 0.0 | -0.1 | -0.3 | -1.5 | | | |
| Pre-tax income | -4.5 | -6.2 | -2.9 | -2.7 | -3.3 | -2.7 | -0.2 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -4.5 | -6.4 | -2.9 | -2.7 | -3.3 | -2.7 | -0.2 |
| Net margin | -215.6% | -448.1% | -310.8% | -734.3% | -1358.1% | | |
| |
| Basic EPS [+] | ($0.53) | ($0.80) | ($0.51) | ($0.50) | ($0.62) | ($0.14) | ($0.01) |
| Growth | -34.0% | 58.1% | 1.3% | -19.4% | 347.5% | 1850.2% | |
| Diluted EPS [+] | ($0.53) | ($0.80) | ($0.51) | ($0.50) | ($0.62) | ($0.14) | ($0.01) |
| Growth | -34.0% | 58.1% | 1.3% | -19.4% | 347.5% | 1850.2% | |
| |
| Shares outstanding (basic) [+] | 8.5 | 7.9 | 5.8 | 5.4 | 5.4 | 19.2 | 21.2 |
| Growth | 6.6% | 37.5% | 6.4% | 1.3% | -72.1% | -9.4% | |
| Shares outstanding (diluted) [+] | 8.5 | 7.9 | 5.8 | 5.4 | 5.4 | 19.2 | 21.2 |
| Growth | 6.6% | 37.5% | 6.4% | 1.3% | -72.1% | -9.4% | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |